Global Healthcare Investment Report: 182 Financing Rounds Raise $5.36 Billion in December 2025

Jan 09, 2026 17:50 CST Updated 17:50

Mindray Scientific

Developer and Manufacturer of Medical Materials and Devices

According to incomplete statistics from Arterial Intelligence, in December 2025, there were a total of 182 financing events in the global healthcare sector (excluding IPOs, private placements, etc.), with disclosed financing amounting to approximately $5.362 billion (about 38.272 billion RMB). Among these, 102 financing events occurred in the Chinese market, with disclosed financing totaling approximately $2.08 billion; overseas markets saw 80 financing events, with disclosed financing amounting to approximately $3.282 billion.

Comparison of Global Healthcare Industry Financing Events from July 2025 to December 2025

Compared with the global healthcare industry's investment and financing situation in November 2025, in terms of transaction amounts, the number of financing events, and focus on emerging fields, the scale of global healthcare industry financing in December 2025 showed an upward trend. The total financing amount increased by approximately 46.73% month-over-month, and the number of events increased by about 30.94% month-over-month.

In terms of large-scale financing events, there were 19 deals exceeding 100 million US dollars this month, with a cumulative financing amount reaching 2.741 billion US dollars. Among these, 12 occurred in overseas regions and 7 took place within China. These 19 companies are: Wuhan Mindray Scientific, a developer and producer of medical materials and medical devices; Tebra, a provider of digital platforms for independent healthcare practices; Blue Sail Health Technology, a producer of nitrile gloves; Syremis Therapeutics, a developer of drugs for the treatment of mental illnesses; Impulse Dynamics, a developer of medical devices for chronic heart failure; Curative, a provider of health insurance services; Aipuqiang, a developer and producer of proton therapy equipment; Angle Health, a full-stack health insurance service provider; Chai Discovery, a developer of drug discovery platforms; Protego Biopharma, a developer of small molecule therapies; Ambros Therapeutics, a biotechnology researcher; Atavistik Bio, a developer of pharmaceutical compounds; Triana Biomedicines, a developer of molecular glue therapeutics; Deep Potential Technology, a developer of simulation R&D platforms; Shengyin Bio, a developer of small nucleic acid drugs; Sidera Bio, a developer of gene research platforms; Deyi Medicine, a developer of precision treatments for tumors and immunology; SureTech, a developer and producer of surgical robots; and Addition Therapeutics, a developer of gene therapies.

Financing Situation in Sub-sectors of the Global Medical and Health Industry by December 2025

In terms of global healthcare industry financing, compared to medical devices and consumables, digital health, medical services, and pharmaceutical commerce, the biopharmaceutical sector took the lead in December with 80 financing events, accounting for 43.96% of the entire field. The total financing amount was approximately US$2.791 billion, representing 52.05% of the entire field.

Notably, Mindray Scientific, a developer and producer of medical materials and devices based in Wuhan, has completed its Series A funding round of 2 billion RMB, securing the top spot for this month's financing. Wuhan Mindray Scientific Co., Ltd. is a comprehensive enterprise in Central China that produces high-value orthopedic implants, integrating research, manufacturing, and trade. It is recognized as a leading company in niche areas of Hubei Province’s pillar industries and is also designated as a "specialized, refined, distinctive, and innovative" little giant enterprise by the state. The company's product range covers four major categories in orthopedics: joints, trauma, spine, and biomaterials, with over 120 varieties and more than 20,000 specifications. Its key technologies, processes, and performance metrics are at an advanced level in China, with its spinal and artificial joint products listed in the directory of excellent domestically produced medical devices. Centered in Wuhan, the company has established marketing and logistics platforms, with a sales network covering all of China, serving more than 1,500 medical institutions. Its products are exported to countries and regions in Asia, Africa, and Latin America. The company places great emphasis on product development, boasting a research team of nearly 140 people, filing nearly 300 patent applications, and allocating over 14% of its annual revenue to R&D. Currently, it has built three key platforms: a 3D printing process platform, an orthopedic biomechanics testing platform, and an orthopedic biomechanical analysis platform.

Major Financing Events in the Global Healthcare Industry - December 2025

Sureflex® Robot Completes D-Round Financing, Accelerating Global Layout of Single-Port Surgical Robots

On December 31, 2025, Beijing Surgerii Robotics Co., Ltd. completed a $100 million financing round. This round was led continuously by Loyal Valley Capital, with additional investments from Shanghai BioPharmaceutical Fund, V Star Capital, DNV Capital, Hefei Industrial Investment, and others. The funds will mainly be used to advance the clinical application and market promotion of products across multiple departments domestically and internationally, as well as to develop the next generation of products, further solidifying the company's leading position in the global single-port surgical robot field.

Injecting "Strong Particles" into Healthy China: Aipuqiang Completes Nearly 1 Billion Yuan B-Round Financing, Leading a New Era of Particle Therapy Made in China

On December 27, 2025, Shanghai Aipuqiang Particle Equipment Co., Ltd. announced the successful completion of a nearly 1 billion RMB B-round financing. This round of financing was jointly led by Shanghai Lianxin, Qianji Capital, Foteng Capital affiliated with Shanghai Guotou, Kechuang Investment, and Taikang Group; multiple institutions including Shanghai Xintou, Liansheng Capital, Zizhu Fengwu, Juhua Hefeng, Ruili Fund, Songqing Capital, Jiading Industrial Zone, Zhongke Park, Xuhui Kechuang Investment, Wenguo Investment, Haiwang Capital, and Xinding Capital participated in the follow-up investment. Notably, market-based funds accounted for more than two-thirds of this financing, demonstrating the market's recognition and support for Aipuqiang’s development prospects. Meanwhile, the company's controlling shareholder, Shanghai Lianhe Investment Co., Ltd., also continued to increase its investment, continuously empowering the company’s long-term development.

Deep Potential Tech Completes C Round Financing Totaling Over 800 Million RMB

On December 24, 2025, DP Technology completed its Series C financing round, raising over 800 million RMB. This round was jointly funded by institutions such as Fortune Venture Capital, Jingguorui Fund, Beijing Artificial Intelligence Industry Investment Fund, Beijing Pharmaceutical and Health Industry Investment Fund, Legend Capital, and Oriza Ventures. The funds from this round will primarily be used to continuously attract and cultivate top talents in the industry, further evolve and iterate DP Technology's "Intelligent Engine for Scientific Discovery," strengthen the full-stack capabilities from original technological innovation to intelligent research tools, products, and industry solutions, and accelerate the market expansion and large-scale application of intelligent products and services around scientific discovery in fields such as fundamental research, life sciences, and material sciences. The completion of this financing marks a solid step forward in DP Technology’s journey to build a new generation of intelligent engines for scientific discovery.

Atavistik Bio, a drug compound developer, completes $120 million Series B financing to advance the development of selective allosteric small molecule therapies for treating Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs).

On December 18, 2025, Atavistik Bio, a drug compound developer, completed a $120 million Series B financing round co-led by Nextech Invest and The Column Group, with participation from existing investor Lux Capital and new investor Regeneron Ventures. Atavistik Bio will use the proceeds from the Series B financing to advance its oral allosteric AKT1 selective inhibitor for HHT, as well as its JAK2 V617F mutation selective inhibitor program for MPNs, through clinical proof-of-concept.

CNS Drug Developer Syremis Therapeutics Secures $165 Million in Series A Funding to Advance New Treatments for Mental Disorders

On December 18, 2025, Syremis Therapeutics, a developer of psychiatric treatment drugs, secured $165 million in Series A financing, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV, QVT, and Pictet. Syremis’s lead program, ST-905, is a dual M1/M4 muscarinic agonist in development for schizophrenia and other neuropsychiatric disorders, currently in Phase 1 clinical trials. The molecule’s differentiated potency and favorable drug properties position it as a potential best-in-class treatment across various neuropsychiatric indications and symptoms, with opportunities for once-daily oral administration and long-acting injectable formulations.

$100 Million Financing Round Reveals Stealth Mode, Aiming to Develop Next-Generation Gene Therapy

On December 17, 2025, gene therapy researcher Addition Therapeutics announced the completion of a $100 million financing round. The investor consortium included SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, Gates Foundation, and BEVC. Addition leverages its groundbreaking all-RNA, non-viral, lipid nanoparticle (LNP)-based PRINT™ (Precision RNA-mediated Transgene Insertion) platform to develop safer, more durable, one-time therapies that overcome the limitations of current genetic medicine modalities.

Tebra, a Digital Platform Provider for Independent Healthcare Practices, Secures $250 Million in Equity and Debt Financing

On December 17, 2025, Tebra, a digital platform provider for independent healthcare practices, secured $250 million in equity and debt financing. This round of financing primarily included equity capital led by Hildred, with significant participation from existing investors Toba Capital, Transformation Capital, and HLM Venture Partners, as well as debt financing provided by J.P. Morgan. Headquartered in Newport Beach, California, Tebra is a trusted leading partner for independent clinics, aiming to bring modernized care to patients around the world.

Biotech Company Ambros Therapeutics Secures $125 Million Series A Financing to Advance Neridronate into Phase 3 Registration Program for Complex Regional Pain Syndrome Type 1

On December 16, 2025, biotechnology company Ambros Therapeutics secured a $125 million Series A financing round, co-led by RA Capital Management and Enavate Sciences, a platform under Patient Square Capital. Participants included Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, Adage Capital Partners LP, and other specialized life science investors. The funds will support the pivotal Phase III clinical trial of Neridronate in CRPS-1 (CRPS-RISE), as well as related regulatory preparations and pre-commercial activities.

Blue Sail Medical's $200 Million Overseas Investment in Place, Integrating Glove Production Capacity and Expanding Upstream Energy

On December 16, 2025, Blue Sail Medical announced that there had been new developments regarding its wholly-owned subsidiary, Shandong Blue Sail Health Technology Co., Ltd., introducing Thai industrial investor Hua Kee Co., Ltd. through a capital increase and share expansion. HKG completed the full $200 million investment in Shandong Health Technology on December 12. This investment will be used for integrating two nitrile glove bases under Blue Sail Medical and acquiring a controlling stake in Zibo Hongda Thermal Power Co., Ltd., among other matters. With the completion of the investment, the above-mentioned asset integration and acquisition matters were also disclosed simultaneously. Blue Sail Medical stated that this move would achieve operational integration and extend the industry chain upstream to energy, transforming "new construction increments" that exacerbate supply-demand imbalances into "integrated existing assets." After the transaction is completed, HKG will hold a total of 40.17% of Shandong Health Technology’s shares, and Blue Sail Medical will remain the controlling shareholder of Shandong Health Technology. With the injection of HKG funds, Shandong Health Technology has simultaneously initiated multiple asset integration actions.

Chai Discovery, a drug discovery platform developer, announces $130 million Series B financing to revolutionize the field of molecular discovery

On December 15, 2025, Chai Discovery, a developer of drug discovery platforms, announced the completion of a $130 million Series B financing round co-led by Oak HC/FT and General Catalyst, with participation from Thrive Capital, OpenAI, Dimension, Menlo Ventures, Lachy Groom, Yosemite, Neo, and SV Angel. New investors Emerson Collective and Glade Brook also joined this round. The company will use the funds to accelerate R&D and product development, expand commercialization efforts, and continue advancing its vision of building a molecular "computer-aided design suite."

$109 Million + China's Innovative Drugs, Danish Biotech Invests Heavily in Obesity Sector

December 10, 2025. Sidera Bio, a Danish emerging biotechnology company, announced the successful completion of a Series A financing round worth 700 million Danish kroner (approximately 109 million US dollars). The institutions participating in this round of investment include a strong lineup such as Novo Holdings, Forbion, RA Capital Healthcare Fund, and Gilde Healthcare, which are top global venture capital firms in the healthcare field. The smooth progress of this financing and licensing collaboration will provide strong support for Sidera Bio's R&D and commercialization efforts in the field of obesity treatment.

Chronic Heart Failure Medical Device Developer Impulse Dynamics Completes $158 Million Financing

On December 10, 2025, Impulse Dynamics, a developer of medical devices for chronic heart failure, completed a $158 million financing round. This substantial investment was supported by new institutional investors, including Sands Capital and Braidwell, and bolstered by returning investors Redmile, Perceptive, and Alger, as well as several prominent industry executives. This significant investment reflects the investors' strong confidence and commitment to the company's vision and expansion, aimed at driving commercialization and advancing clinical and technological processes.

D3 Bio Completes $108 Million Series B Financing to Accelerate Development of Innovative Oncology Therapies

On December 10, 2025, D3 Bio recently completed a $108 million Series B financing round, which was jointly participated by a group of well-known investment institutions, including IDG Capital and Songqing Capital. Existing investors of the company include WuXi AppTec Ventures, Temasek, Sequoia China, Matrix Partners, and Medicxi, who continued to increase their investments. The proceeds from this round of financing will be mainly used to support the global Phase III pivotal clinical study of the company's core candidate drug elisrasib (D3S-001). This study will evaluate the application of elisrasib as both monotherapy and combination therapy in patients with KRAS G12C mutant tumors, covering major countries and regions such as the United States, China, and the European Union, to support subsequent global registration filings.

Focused on Innovative RNAi Therapy Development, SinoBiopharma Completes Over $1.1 Billion in Series B Financing

On December 9, 2025, Saint Biologics announced the completion of a Series B financing round exceeding US$110 million. This round was led by a renowned industrial organization, with participation from an international sovereign fund, China Biopharmaceutical Group, Legend Capital, Vivo Capital, Invus, SymBiosis, Suzhou Venture Capital, Zhenmai Investment, and Lake Bleu Capital. Additionally, strategic investment was provided by Eli Lilly and Company. Existing shareholders including Gaoling & Genesis Capital, Qiming Venture Partners, Kunlun Capital, TF Capital, Oriza Holdings, and Northern Light Venture Capital continued their support. The proceeds from this round will be used to advance the company’s clinical-stage pipeline into registration studies and accelerate the development of multiple therapeutic pipelines across diverse fields, leveraging its globally leading RNAi drug discovery platform — including the LEAD™ (Ligand and Enhancer Assisted Delivery) extrahepatic delivery platform.

Mindray Medical Increases Capital by 20 Billion

On December 8, 2025, Wuhan Mindray Scientific Co., Ltd. underwent a significant transformation in capital operations and enterprise management by completing its Series A financing round. Mindray Medical took over as the controlling shareholder, becoming the largest shareholder of Wuhan Mindray Scientific. At the same time, the registered capital of Wuhan Mindray Scientific increased substantially from 300 million yuan to 2.3 billion yuan, injecting strong momentum for its future development. Additionally, the legal representative changed from Shi Peng to Han Le, indicating a major adjustment in the management team. The new leadership is expected to guide the company into a new phase of development.

Full-stack health insurance service provider Angle Health raises $134 million in Series B funding to expand AI-native health benefits platform for 62 million SME employees

On December 3, 2025, Angle Health, a full-stack health insurance service provider, raised $134 million in Series B funding, led by Portage, with major investors including Blumberg Capital, Mighty Capital, PruVen Capital, SixThirty Ventures, TSVC, Wing VC, and Y Combinator. This round of financing, which includes both debt and equity, brings the total funding to nearly $200 million. The company is scaling up operations to meet the growing market demand for alternative health plan products.

Molecular Glue Therapeutics Developer Triana Biomedicines Completes $120 Million Series B Financing to Develop Novel ALK-Targeted Molecular Glue Degraders

On December 3, 2025, molecular glue therapeutics developer Triana Biomedicines completed a $120 million Series B financing round, co-led by Ascenta Capital and Bessemer Venture Partners. New investors include YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures. TRIANA continues to receive support from existing founding investors RA Capital Management and Atlas Venture, as well as Lightspeed Venture Partners, Pfizer Ventures, and Surveyor Capital. The proceeds will support the development of the lead candidate product TRI-611, an anaplastic lymphoma kinase-positive (ALK) targeted molecular glue degrader for clinical proof-of-concept in ALK+ non-small cell lung cancer (NSCLC), selection of a second candidate product in 2026, and expansion of TRINA's pipeline beyond TRI-611.

Health Insurance Provider Curative Raises $150 Million in Series B Funding to Redefine the Future of Health Insurance

On December 2, 2025, Curative, a health insurance service provider, raised $150 million in Series B funding led by Chris Anderson's Upside Vision Fund, the chairman of TED. Justin Mateen, founder of JAM Fund, also participated in this round of financing, with personal and JAM Fund investments totaling $47.5 million. Other investors include Mike Novogratz of Galaxy Digital, Stanley Druckenmiller’s Duquesne Family Office, DCVC, and Martin Varsavsky. The Series B capital injection will support Curative in achieving its goal of nationwide expansion in China, with near-term targets including the Mid-Atlantic states, building on its existing service areas in Texas, Florida, and Georgia.

Small Molecule Therapy Developer Protego Biopharma Secures $130 Million in Series B Financing to Advance First AL Amyloidosis Program into Pivotal Study Phase

On December 1, 2025, small molecule therapy developer Protego Biopharma secured $130 million in Series B funding. The round was led by Novartis Venture Fund and Forbion, with new investors including Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures. Existing investors such as Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research also participated in the round. The proceeds will drive Protego's lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis, a rare and often fatal disease caused by protein misfolding, particularly affecting cardiac organs.

Welcome ImmediatelyScan the QR code to add the assistantObtainCompleteMonthly ReportAndApply for a Free Trial of the Database, if added, please ask proactively: